REG - Adv Medical Solutns. - Director/PDMR Shareholding

Advanced Medical SolutionsAnnouncement

15/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241115:nRSO3393Ma&default-theme=true

RNS Number : 3393M  Advanced Medical Solutions Grp PLC  15 November 2024

     15 November 2024

            Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

 

            Director/PDMR Shareholding

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the
world-leading specialist in tissue-healing technologies, announces the
following Director share transactions.

 

As part of the Share Incentive Plan ("SIP"), previously referred to as the
Deferred Share Bonus Plan ("DSB"), Executive Directors and employees can
sacrifice part of their annual bonus and/or salary in the SIP, which for every
share purchased on behalf of the employee they receive matching shares which
are deferred for a minimum of three years. Chris Meredith (CEO) and Eddie
Johnson (CFO) have elected to sell certain existing shares to use the proceeds
to re-invest in the SIP.

 

The Company was notified on 11 November 2024 that following his decision to
participate Chris  Meredith, who is a Director and PDMR, executed the sale
29,199 Ordinary Shares of 5p from the existing SIP on 11 November 2024 at a
share price of 218.37p per Ordinary Share. The proceeds from the sale of the
shares were used to purchase shares in the SIP, as detailed below.

 

The Company was further notified on 11 November 2024 that following his
decision to participate Eddie Johnson, who is a Director and PDMR, executed
the exercise of 34,235 options from the existing Long Term Incentive Plan
("LTIP") and subsequently sold 34,235 Ordinary Shares of 5p each on 11
November 2024 at a share price of 217.58p per Ordinary Share. The proceeds
from the sale of the shares were used to purchase shares in the SIP, as
detailed below. The number of shares held by Eddie Johnson and his PCAs will
increase his beneficial interest in the Company from the level prior to these
transactions.

 

The Trust which manages the SIP on behalf of the employees of AMS has
purchased Ordinary Shares of 5p each ("Ordinary Shares") on 12 November 2024,
at a share price of 224.50p on behalf of Chris Meredith (26,089 Ordinary
Shares) and Eddie Johnson (17,229 Ordinary Shares), who are both
Directors/PDMRs, as part of the SIP and, under the terms of the SIP, these
shares will be held in trust on their behalf.

 

Following these transactions the beneficial ownership of Chris Meredith and
Eddie Johnson are as follows:

 

 Director/PDMR             Date purchased    Shares purchased (through SIP)  Resultant holding  % of issued share capital
 Chris Meredith            12 November 2024  26,089                          1,817,211          0.83%

 Chief Executive Officer
 Eddie Johnson             12 November 2024  17,229                          169,731            0.08%

 Chief Financial Officer

 

The notification below, made in accordance with the requirements of the EU
Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name: Chris Meredith
 2.  Reason for the notification
 a)  Position/status: Chief Executive Officer
 b)  Initial notification/Amendment: Initial Notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name:   Advanced Medical Solutions Group plc
 b)  LEI: 213800HJP6OWOSZI1L74
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument: Ordinary Shares
     of 5p

     Identification code: GB0004536594
 b)  Nature of the transactions:

     ·        Sale of Ordinary Shares of 5p Share Incentive Plan

     ·        Purchase of Ordinary Shares as part of the Share Incentive
     Plan on 12 November 2024
 c)  Price(s) and volume(s):

Price(s)                                      Volume(s)
     Sale of shares from SIP at 218.37p per share  29,199
     Purchase by SIP at 224.50p per share          26,089
 d)  Aggregated information:

     Aggregated volume: n/a

     Aggregated price: n/a
 e)  Date of the transactions: 11/11/2024 and 12/11/2024
 f)  Place of the transaction: London Stock Exchange (XLON)

d)

Aggregated information:

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transactions: 11/11/2024 and 12/11/2024

f)

Place of the transaction: London Stock Exchange (XLON)

 

 

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name: Eddie Johnson
 2.  Reason for the notification
 a)  Position/status: Chief Financial Officer
 b)  Initial notification/Amendment: Initial Notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name:   Advanced Medical Solutions Group plc
 b)  LEI: 213800HJP6OWOSZI1L74
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument: Ordinary Shares
     of 5p

     Identification code: GB0004536594
 b)  Nature of the transactions:

     ·        Exercise of options from the LTIP

     ·        Sale of Ordinary Shares of 5p

     ·        Purchase of Ordinary Shares as part of the Share Incentive
     Plan on 12 November 2024
 c)  Price(s) and volume(s):

Price(s)                                   Volume(s)
     Exercise of options from LTIP at nil cost  34,235
     Sale of shares at  217.58p per share       34,235
     Purchase by SIP at 224.50p per share       17,229
 d)  Aggregated information:

     Aggregated volume: n/a

     Aggregated price: n/a
 e)  Date of the transactions: 11/11/2024 and 12/11/2024
 f)  Place of the transaction: London Stock Exchange (XLON)

d)

Aggregated information:

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transactions: 11/11/2024 and 12/11/2024

f)

Place of the transaction: London Stock Exchange (XLON)

 

- Ends -

 

For further information, please visit www.admedsol.com
(http://www.admedsol.com) or contact:

 

 Advanced Medical Solutions Group plc     Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Michael King, Investor Relations

 ICR Consilium                            Tel: +44 (0) 20 3709 5700
 Mary-Jane Elliott / Lucy Featherstone    AMS@consilium-comms.com

 Investec Bank PLC (NOMAD & Broker)       Tel: +44 (0) 20 7597 5970
 Gary Clarence / David Anderson

 HSBC Bank PLC (Broker)                   Tel: 44 (0) 20 7991 8888
 Joe Weaving / Stephanie Cornish

 

About Advanced Medical Solutions Group plc - see www.admedsol.com
(http://www.admedsol.com)

AMS is a world-leading independent developer and manufacturer of innovative
tissue-healing technology, focused on quality outcomes for patients and value
for payers. AMS has a wide range of surgical products including tissue
adhesives, sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand®, RESORBA®,
LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and
Seal-G®. AMS also supplies wound care dressings such as silver alginates,
alginates and foams through its ActivHeal® brand as well as under white
label. Since 2019, the Group has made seven acquisitions: Sealantis, an
Israeli developer of innovative internal sealants, Biomatlante, a French
developer and manufacturer of surgical biomaterials, Raleigh, a leading UK
coater and converter of woundcare and bio-diagnostics materials, AFS Medical,
an Austrian specialist surgical business, Connexicon, an Irish tissue
adhesives specialist, Syntacoll, a German specialist in collagen-based
absorbable surgical implants and Peters Surgical, a global provider of
specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate
devices.

AMS's products, manufactured in the UK, Germany, France, the Netherlands,
Thailand, India, the Czech Republic and Israel, are sold globally via a
network of multinational or regional partners and distributors, as well as via
AMS's own direct sales forces in the UK, Germany, Austria, France, Poland,
Benelux, India, the Czech Republic and Russia. The Group has R&D
innovation hubs in the UK, Ireland, Germany, France and Israel. Established in
1991, the Group has more than 1,500 employees. For more information, please
see www.admedsol.com (http://www.admedsol.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBCBDBLDBDGSS